Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2020-01-02 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第七届董事会第十九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting, specifically about the appointment of the company's general manager and other senior management personnel. It includes voting results and references compliance with company law and articles of association. There is no financial data or report content, only management appointment information. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2020-01-02 Chinese
第七届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 普洛药业股份有限公司 regarding the approval of a proposal about using idle funds to purchase financial products. It includes voting results and confirms compliance with company law and articles of association. The document is short (479 characters) and is an official announcement of a board meeting decision, not a full report or financial statement. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a shareholder voting result announcement (DVA) since it is a supervisory board meeting, not a shareholder meeting. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-01-01 Chinese
独立董事关于对公司购买基金理财产品暨关联交易事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding a related-party transaction involving the purchase of fund financial products. It references compliance with regulatory guidelines and company rules, and provides an independent opinion on the transaction's fairness and legality. The document is short (589 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or financial supplement. It is a governance-related document concerning board oversight and approval of a transaction. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2020-01-01 Chinese
关于使用自有闲置资金购买基金理财产品暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding the use of idle funds to purchase fund financial products, which is described as a related party transaction. It includes details about the investment plan, the asset manager, risk analysis, independent directors' opinions, and the impact on the company. The document is relatively short (2806 characters) and focuses on a specific financing/investment activity rather than comprehensive financial results or management discussion. It does not contain financial statements or detailed financial performance data. The content aligns with updates on company financing activities and capital usage. Therefore, the document fits best under Capital/Financing Update (CAP).
2020-01-01 Chinese
第七届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 普洛药业股份有限公司, detailing the approval of a proposal regarding the use of idle funds to purchase financial products. It includes information about the meeting date, attendance, voting results, and compliance with company law and articles of association. There is no detailed financial data, no annual or interim report content, no audit information, nor is it a transcript or presentation. It is a formal announcement of a board decision, which fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or announcement of a report publication.
2020-01-01 Chinese
独立董事关于对公司购买基金理财产品暨关联交易事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding the prior approval of a related party transaction involving the purchase of fund products. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (419 characters) and serves as an official opinion or certification rather than a full report. It is not an annual report, audit report, or financial supplement. It is also not a management change, earnings release, or capital update. The content fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure related to corporate governance and compliance with related party transaction rules.
2020-01-01 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.